Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Aprazer Healthcare Pvt Ltd
28 tablet
Velpatasvir and Sofosbuvir
Keep in cold place
Delivering To:
Overview
Velakast Tablet is a combination of Sofosbuvir and Velpatasvir, used to treat chronic (long-lasting) Hepatitis C Virus in adults. It slows the multiplication process of the virus and helps the immune system fight against the infection. Velakast is a fixed-dose tablet for oral administration. It is advised to take the dose every day at the same time. It may help your liver to recover.
Hepatitis C
Treatment of Chronic hepatitis C virus (HCV) infection
Velakast tablets may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.
Nausea
Vomiting
Insomnia
Weight loss
Headache
Tiredness
Fatigue
Diarrhea
Urine infection
Dark colored urine
Your healthcare provider will prescribe you the dose according to the severity of the disease. Take the dose exactly as prescribed, without any alteration/manipulation.
Please contact your healthcare provider immediately in case of an overdose.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Velakast tablets without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Velakast tablets without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
If you miss a dose of Velakast tablets, take it as soon as you remember. If it is already the time for the next dose, do not take 2 doses. Do not double the doses to catch up.
Velakast is a combination of Sofosbuvir and Velpatasvir, used to treat chronic (long-lasting) Hepatitis C Virus in adults.
Take Velakast exactly as your healthcare provider tells you. Do not crush, chew, or break the tablet. Swallow it as a whole.
There can be side effects such as nausea, vomiting, insomnia, fatigue, urine infection, dark-colored urine, headache, and diarrhea. Please consult your healthcare provider if you experience these or any other side effects.
If you miss a dose, take it as soon as you remember. Do not take the missed dose if it is already the time for the next dose.
Your healthcare provider can make this clear if Velakast is safe for consumption during breastfeeding or not.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Efficacy and safety of direct‑acting antiviral regimen for patients with hepatitis C virus genotype 2: A systematic review and meta‑analysis. (2024). BMC Gastroenterology, 24, Article 34? BioMed Central Sofosbuvir/velpatasvir in decompensated cirrhotic patients with genotype 1 and 2: A prospective multicenter real-world study in India. (2024). Journal of Clinical and Experimental Hepatology. PubMed+1jcehepatology.com+1
Sofosbuvir/velpatasvir/voxilaprevir for Hepatitis C virus retreatment in difficult‑to‑treat patients: A real‑life observational study from India. (2023). Journal of Clinical and Experimental Hepatology Sofosbuvir–velpatasvir single‑tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. (2023). BMC Medicine / multicenter Indian cohort. PMC
Aprazer Healthcare Pvt Ltd
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.